TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25431805

Group type: EXPERIMENTAL
Intervention: Aloe vera mouthwash
Number of subjects: 26

Group type: COMPARATOR
Intervention: Benzydamine mouthwash
Number of subjects: 26
Study: 24330749

Group type: EXPERIMENTAL
Intervention: Prism intervention with training and support
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prism intervention
Number of subjects: 0
Study: 21554128

Group type: EXPERIMENTAL
Intervention: Saw palmetto given at escalating doses over an 18-month period
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Mass mailing and advertising recruitment methods
Number of subjects: 350

Group type: COMPARATOR
Intervention: Comparison with MTOPS participants
Number of subjects: 350
Study: 18315429

Group type: EXPERIMENTAL
Intervention: Subantimicrobial dose doxycycline (SDD) 20 mg, twice a day for 3 months plus scaling and root planing
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo capsules, twice a day for 3 months plus scaling and root planing
Number of subjects: 30
Study: 16513078

Group type: EXPERIMENTAL
Intervention: Pyrimethamine-sulfadoxine (PS) treatment
Number of subjects: 291
Study: 11790519

Group type: EXPERIMENTAL
Intervention: Tricyclic antidepressant (TCA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Monoamine oxidase inhibitor
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alternative treatment for nonresponders
Number of subjects: 0
Study: 10195319

Group type: EXPERIMENTAL
Intervention: Grief counseling (13 sessions over 4 months)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Widows (experimental group)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Widows (non-experimental group)
Number of subjects: 28
Study: 8789577

Group type: EXPERIMENTAL
Intervention: Ubiquinone supplementation (120 mg.day‐1 for 6 weeks)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Ubiquinone supplementation
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Ubiquinone supplementation and exercise
Number of subjects: 19
Study: 2405805

Group type: EXPERIMENTAL
Intervention: Low-fat eating plan with nutritional and behavioral counseling and social support
Number of subjects: 303

Group type: COMPARATOR
Intervention: Customary diet
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Low-fat eating plan
Number of subjects: 303
Study: 518441

Group type: EXPERIMENTAL
Intervention: High-pressure air environments
Number of subjects: 8

Group type: COMPARATOR
Intervention: Low pressure
Number of subjects: 8
Study: 6656327

Group type: EXPERIMENTAL
Intervention: Routine care and periodic home visits by nurses or pharmacists
Number of subjects: 171

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Home visits and family members monitoring blood pressure and compliance behavior
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Home visits alone
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: High-risk characteristics
Number of subjects: 171
Study: 31442936

Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Foster care
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Never institutionalized controls
Number of subjects: 216
Study: 30203754

Group type: EXPERIMENTAL
Intervention: Sequential therapy with azithromycin
Number of subjects: 160
Study: 26864309

Group type: EXPERIMENTAL
Intervention: Functional-Movement Training (FMT)
Number of subjects: 88
Study: 24401727

Group type: EXPERIMENTAL
Intervention: Exenatide once weekly (2 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 22732201

Group type: EXPERIMENTAL
Intervention: Coronary CTA
Number of subjects: 180

Group type: COMPARATOR
Intervention: MPS
Number of subjects: 180
Study: 19781120

Group type: EXPERIMENTAL
Intervention: Beta-glucan soup (3.5 g/d) for 8 weeks
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control soup (without beta-glucan) for 8 weeks
Number of subjects: 53
Study: 17268215

Group type: EXPERIMENTAL
Intervention: valsartan 160 mg
Number of subjects: 4278

Group type: EXPERIMENTAL
Intervention: valsartan/hydrochlorothiazide 320/25 mg
Number of subjects: 4278

Group type: EXPERIMENTAL
Intervention: valsartan/hydrochlorothiazide (combination therapy)
Number of subjects: 4278

Group type: EXPERIMENTAL
Intervention: valsartan (incremental doses)
Number of subjects: 4278

Group type: COMPARATOR
Intervention: valsartan 80 mg
Number of subjects: 4278
Study: 15574531

Group type: EXPERIMENTAL
Intervention: Social ecological interventions to promote dual protection
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Interventions at structural/environmental, social/interpersonal, and individual levels
Number of subjects: 48
Study: 12232492

Group type: EXPERIMENTAL
Intervention: Real acupuncture
Number of subjects: 45

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 45
Study: 10414570

Group type: EXPERIMENTAL
Intervention: A1-A2 angle in patients with ACoA aneurysms (normoplastic A1 segments)
Number of subjects: 63

Group type: COMPARATOR
Intervention: A1-A2 angle in control subjects without ACoA aneurysms
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: A1-A2 angle associated with ACoA aneurysms
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: A1-A2 angle on the non-aneurysm side in patients with ACoA aneurysms
Number of subjects: 63
Study: 7477167

Group type: EXPERIMENTAL
Intervention: Ritonavir (600 mg every 12 hours)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Ritonavir (higher-dosage groups)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study: 1979634

Group type: EXPERIMENTAL
Intervention: beta-blocker/diuretic combination
Number of subjects: 20

Group type: COMPARATOR
Intervention: reserpine-containing combination
Number of subjects: 20
Study: 7013060

Group type: EXPERIMENTAL
Intervention: Methylprednisolone (30 mg per kg body weight)
Number of subjects: 20

Group type: COMPARATOR
Intervention: No steroids (control group)
Number of subjects: 20
Study: 31789486

Group type: EXPERIMENTAL
Intervention: Drug-coated balloon (DCB) treatment for early DES-ISR
Number of subjects: 352

Group type: COMPARATOR
Intervention: Drug-coated balloon (DCB) treatment for late DES-ISR
Number of subjects: 352
Study: 31163212

Group type: EXPERIMENTAL
Intervention: SSRIs (escitalopram or sertraline) for 12 weeks
Number of subjects: 42
Study: 30053031

Group type: EXPERIMENTAL
Intervention: Hyperosmolar saline (1500 mOsm/L)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Isoosmolar saline (300 mOsm/L)
Number of subjects: 18
Study: 27000402

Group type: EXPERIMENTAL
Intervention: SIPsmartER
Number of subjects: 301

Group type: COMPARATOR
Intervention: MoveMore
Number of subjects: 301
Study: 24440015

Group type: EXPERIMENTAL
Intervention: Optimal medical therapy (OMT) + percutaneous coronary intervention (PCI)
Number of subjects: 621

Group type: COMPARATOR
Intervention: Optimal medical therapy (OMT) alone
Number of subjects: 621

Group type: EXPERIMENTAL
Intervention: Ischemic burden
Number of subjects: 621

Group type: EXPERIMENTAL
Intervention: Combination of anatomic and ischemic burden
Number of subjects: 621
Study: 22878257

Group type: EXPERIMENTAL
Intervention: The11 injury prevention programme (performed in each practice session during one soccer season)
Number of subjects: 456

Group type: COMPARATOR
Intervention: Control group (continued practice sessions as usual)
Number of subjects: 456

Group type: EXPERIMENTAL
Intervention: The11 injury prevention programme
Number of subjects: 456

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 456
Study: 20200420

Group type: EXPERIMENTAL
Intervention: Glycine buffer (pH 11.1)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Water (pH 6.8)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Biomimetic remineralizing medium
Number of subjects: 2
Study: 17533529

Group type: EXPERIMENTAL
Intervention: Thyroid Lead Shield
Number of subjects: 65

Group type: COMPARATOR
Intervention: No Thyroid Shield
Number of subjects: 65
Study: 16135593

Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 15
Study: 12970667

Group type: EXPERIMENTAL
Intervention: Self-etching primer group
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional etching and priming group
Number of subjects: 20
Study: 10071526

Group type: COMPARATOR
Intervention: Albuterol aerosol (180 micrograms)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Salmeterol powder (25 micrograms)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Salmeterol powder (50 micrograms)
Number of subjects: 0
Study: 7482103

Group type: EXPERIMENTAL
Intervention: Incision and drainage
Number of subjects: 27

Group type: COMPARATOR
Intervention: Needle aspiration
Number of subjects: 27
Study: 2405200

Group type: EXPERIMENTAL
Intervention: Transperitoneal approach
Number of subjects: 113

Group type: COMPARATOR
Intervention: Retroperitoneal approach
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Transperitoneal and Retroperitoneal approaches (compared to retrospective data)
Number of subjects: 113
Study: 6795049

Group type: EXPERIMENTAL
Intervention: Glucose infusion
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Intralipid plus glucose infusion
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 22
Study: 31629615

Group type: EXPERIMENTAL
Intervention: Clinical pathway‐ Problem based Learning (CP‐PBL)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Lecture based Learning (LBL) only
Number of subjects: 106
Study: 30215723

Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Ziprasidone
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 202
Study: 26935876

Group type: EXPERIMENTAL
Intervention: Vonoprazan 20 mg as part of first-line triple therapy (with amoxicillin 750 mg and clarithromycin 200 or 400 mg)
Number of subjects: 650

Group type: COMPARATOR
Intervention: Lansoprazole 30 mg as part of first-line triple therapy (with amoxicillin 750 mg and clarithromycin 200 or 400 mg)
Number of subjects: 650

Group type: EXPERIMENTAL
Intervention: Second-line vonoprazan-based triple therapy (with amoxicillin 750 mg and metronidazole 250 mg)
Number of subjects: 650
Study: 24662210

Group type: EXPERIMENTAL
Intervention: Matched treatment (trunk stabilization exercise)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Unmatched treatment (Movement System Impairment‐directed exercises)
Number of subjects: 124
Study: 22257523

Group type: COMPARATOR
Intervention: Chemotherapy with trastuzumab (ECH-TH group)
Number of subjects: 620

Group type: EXPERIMENTAL
Intervention: Chemotherapy with lapatinib (ECL-TL group)
Number of subjects: 620
Study: 18829075

Group type: EXPERIMENTAL
Intervention: Single apical injection of 5 mL lidocaine
Number of subjects: 117

Group type: COMPARATOR
Intervention: Bilateral basal injection of 2 injections of 5 mL lidocaine
Number of subjects: 117
Study: 17761060

Group type: EXPERIMENTAL
Intervention: Case conferences
Number of subjects: 738

Group type: COMPARATOR
Intervention: Written feedback
Number of subjects: 738
Study: 15040542

Group type: EXPERIMENTAL
Intervention: LPV/ritonavir (LPV/r) in combination with other antiretroviral agents
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: LPV/ritonavir (LPV/r)
Number of subjects: 22
Study: 12238823

Group type: EXPERIMENTAL
Intervention: On-pump beating heart valvular operations using retrograde coronary sinus perfusion
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional valvular operation using retrograde continuous warm blood cardioplegia
Number of subjects: 50
Study: 9730852

Group type: EXPERIMENTAL
Intervention: Subcutaneous GLP-1 (3 times a day before meals)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Saline (3 times a day before meals)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Subcutaneous GLP-1
Number of subjects: 6
Study: 7914733

Group type: EXPERIMENTAL
Intervention: L-carnitine (6 g/day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 3197094

Group type: EXPERIMENTAL
Intervention: Metoclopramide
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Prochlorperazine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 29587655

Group type: EXPERIMENTAL
Intervention: 6 mg levobupivacaine combined with fentanyl (GL6)
Number of subjects: 62

Group type: COMPARATOR
Intervention: 8 mg levobupivacaine combined with fentanyl (GL8)
Number of subjects: 62
Study: 26773672

Group type: EXPERIMENTAL
Intervention: Motivational interviewing during 5 sessions
Number of subjects: 56

Group type: COMPARATOR
Intervention: Health-care services (Control)
Number of subjects: 56
Study: 24766732

Group type: EXPERIMENTAL
Intervention: Axitinib at a starting dose of 5-mg twice daily continuously plus pemetrexed 500 mg/m² and cisplatin 75 mg/m² on day 1 of up to six 21-day cycles (arm I)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Axitinib on days 2 through 19 of each cycle plus pemetrexed/cisplatin (arm II)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Pemetrexed/cisplatin alone (arm III)
Number of subjects: 170
Study: 22823091

Group type: EXPERIMENTAL
Intervention: Comprehensive intervention using a community organizing approach implemented over 3 years
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher levels of implementation of the intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison condition (control group)
Number of subjects: 0
Study: 20003124

Group type: EXPERIMENTAL
Intervention: Bolus dose of propofol 1.8 mg/kg at a rate of 1200 ml/h
Number of subjects: 16

Group type: COMPARATOR
Intervention: Infusion of propofol 12 mg/kg/h
Number of subjects: 16
Study: 18668408

Group type: EXPERIMENTAL
Intervention: Diesel exhaust (DE) at 200 microg PM(2.5)/m(3) (DE(200))
Number of subjects: 16

Group type: COMPARATOR
Intervention: Filtered air (FA)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Diesel exhaust (DE) at 100 microg PM(2.5)/m(3) (DE(100))
Number of subjects: 16
Study: 16313113

Group type: EXPERIMENTAL
Intervention: SS syrup
Number of subjects: 38

Group type: COMPARATOR
Intervention: Pilocarpine (control group)
Number of subjects: 38
Study: 12817525

Group type: EXPERIMENTAL
Intervention: Intrathecal ziconotide (1, 5, 7.5, or 10 micrograms)
Number of subjects: 22
Study: 10554645

Group type: COMPARATOR
Intervention: 1 x 8 Gy
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: 10 x 3 Gy
Number of subjects: 107
Study: 8893680

Group type: EXPERIMENTAL
Intervention: Low-dose recombinant FSH (40 cycles)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Low-dose hMG (26 cycles)
Number of subjects: 22
Study: 8295364

Group type: EXPERIMENTAL
Intervention: PhXA41 25 micrograms/ml
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: PhXA41 50 micrograms/ml
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: PhXA41 100 micrograms/ml
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: PhXA41
Number of subjects: 35
Study: 3631982

Group type: EXPERIMENTAL
Intervention: Hydrocolloid occlusive dressing (HCD)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Fluocinolone acetonide cream (twice-daily applications)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Erythemogenic ultraviolet B treatment
Number of subjects: 26
Study: 31868907

Group type: EXPERIMENTAL
Intervention: Molecular panel-guided treatment for selected mutations
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 0
Study: 28332914

Group type: EXPERIMENTAL
Intervention: Working memory (WM) training program
Number of subjects: 34

Group type: COMPARATOR
Intervention: Normal class activities (Control)
Number of subjects: 34
Study: 28125168

Group type: EXPERIMENTAL
Intervention: 5 mg daily oral Prednisone for one month
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 12.5 mg daily oral Prednisone for one month
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 25 mg daily oral Prednisone for one month
Number of subjects: 90
Study: 27275233

Group type: COMPARATOR
Intervention: ICS/LABA
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: ICS/LABA plus Montelukast
Number of subjects: 56
Study: 23040588

Group type: EXPERIMENTAL
Intervention: n-3 to n-6 polyunsaturated fatty acids ratio
Number of subjects: 101
Study: 21769136

Group type: EXPERIMENTAL
Intervention: Integrated care intervention (INT) with counseling and case management for up to 9 months
Number of subjects: 101

Group type: COMPARATOR
Intervention: Standard of care (SC)
Number of subjects: 101
Study: 19336639

Group type: EXPERIMENTAL
Intervention: Sliding‐scale regular insulin (SSRI) alone (n = 25)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Insulin glargine (n = 25)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study: 16397283

Group type: EXPERIMENTAL
Intervention: Otamixaban
Number of subjects: 0
Study: 15000515

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral group treatment
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Interactional group treatment
Number of subjects: 128

Group type: COMPARATOR
Intervention: Psychosocial and biological indicators
Number of subjects: 128
Study: 11080319

Group type: EXPERIMENTAL
Intervention: Vicarious experience through peer support (experimental group)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 56
Study: 8706452

Group type: EXPERIMENTAL
Intervention: Closed-loop control of airway occlusion pressure at 0.1 sec (P0.1)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Pressure-support ventilation adjustments
Number of subjects: 8
Study: 1850686

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of [3H]noradrenaline
Number of subjects: 43

Group type: COMPARATOR
Intervention: Neuronal uptake blockade with desipramine
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Mental arithmetic and isometric handgrip exercise
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Rest in supine position
Number of subjects: 43
Study: 6645778

Group type: EXPERIMENTAL
Intervention: Electric convulsive therapy (ECT)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Premedication only (Control)
Number of subjects: 9
Study: 31396757

Group type: EXPERIMENTAL
Intervention: Walking (for 30 min) immediately after the meal
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Bodyweight exercises (3 sets of 10 squats, 10 push-ups, 10 lunges, 10 sit-ups) immediately after the meal
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Standing still (for 30 min) immediately after the meal
Number of subjects: 48

Group type: COMPARATOR
Intervention: Standing, walking, or bodyweight exercise conducted immediately before the meal
Number of subjects: 48

Group type: COMPARATOR
Intervention: Standing, walking, or bodyweight exercise conducted 30 min after the meal
Number of subjects: 48
Study: 31525122

Group type: EXPERIMENTAL
Intervention: Genetic information about nicotine addiction and lung cancer (n = 314)
Number of subjects: 392

Group type: COMPARATOR
Intervention: News article about pharmacy's decision to stop selling tobacco (n = 78)
Number of subjects: 392
Study: 27378477

Group type: EXPERIMENTAL
Intervention: Small access window (6×6 mm) + bone filling using a special device
Number of subjects: 16

Group type: COMPARATOR
Intervention: Large access window (10×8 mm) + manual bone filling
Number of subjects: 16
Study: 25828280

Group type: EXPERIMENTAL
Intervention: Oxycodone 0.1 mg/kg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normal saline 0.1 ml/kg (Control)
Number of subjects: 60
Study: 23312881

Group type: EXPERIMENTAL
Intervention: Aflibercept 4 mg/kg with irinotecan-LV5FU2 every 2 weeks
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 21166834

Group type: EXPERIMENTAL
Intervention: Neurochemical intervention involving L-theanine and 5-hydroxytryptophan
Number of subjects: 0
Study: 19692885

Group type: EXPERIMENTAL
Intervention: LigaSure (5 to 10 mm)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Endodissector and endoclip
Number of subjects: 32
Study: 17329041

Group type: EXPERIMENTAL
Intervention: Consistent condom use with exclusive main partner
Number of subjects: 1770

Group type: EXPERIMENTAL
Intervention: Consistent condom use with multiple partners
Number of subjects: 1770

Group type: EXPERIMENTAL
Intervention: Anticipating a positive response to requests for condom use
Number of subjects: 1770

Group type: EXPERIMENTAL
Intervention: Partner support of condom use
Number of subjects: 1770

Group type: EXPERIMENTAL
Intervention: Main partner's pregnancy desires
Number of subjects: 1770

Group type: EXPERIMENTAL
Intervention: Needle sharing with a main partner
Number of subjects: 1770

Group type: EXPERIMENTAL
Intervention: Injecting with a used needle
Number of subjects: 1770

Group type: EXPERIMENTAL
Intervention: Intimate partner violence
Number of subjects: 1770
Study: 15114122

Group type: EXPERIMENTAL
Intervention: Injection microdome positioned in the parasternal area
Number of subjects: 260

Group type: COMPARATOR
Intervention: Injection microdome positioned in the lower lateral thoracic area
Number of subjects: 260
Study: 11695500

Group type: EXPERIMENTAL
Intervention: Contextual Memory Test (CMT)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Cued condition (contextual)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Self-awareness estimation
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Use of contextual and association strategies
Number of subjects: 60
Study: 9151028

Group type: EXPERIMENTAL
Intervention: 2.5% hydroxyethyl starch
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 3% gelatin
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 4% human albumin
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control (all groups)
Number of subjects: 36
Study: 7903975

Group type: EXPERIMENTAL
Intervention: CD4 lymphocyte count monitoring
Number of subjects: 1020

Group type: EXPERIMENTAL
Intervention: Proportionate rates of decline in CD4 counts
Number of subjects: 1020

Group type: EXPERIMENTAL
Intervention: Declines in CD4 counts in specific subgroups
Number of subjects: 1020
Study: 3153025

Group type: EXPERIMENTAL
Intervention: Plasma infusions (plasma group, n = 39)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Control group (n = 40)
Number of subjects: 79
Study: 30649925

Group type: EXPERIMENTAL
Intervention: Two continuous glucose monitors (CGMs)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Two insulin pumps
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: All system configurations (using CGMs and insulin pumps)
Number of subjects: 43